PRIMARY OBJECTIVES:
I. To determine the frequency of topoisomerase 2-alpha (TOPO2A) gene copy number
alterations (including deletions, gains, and amplification), immunohistochemical
expression, and chromosome 17 polysomy in tumor tissue samples from patients with
advanced or recurrent endometrial carcinoma treated with anthracycline-based therapy on
Gynecologic Oncology Group (GOG)-0177.
II. To assess the relationship between TOPO2A gene copy number alterations, TOPO2A
protein expression, chromosome 17 polysomy, and human epidermal growth factor receptor 2
(HER2) status in tumor tissue samples from these patients.
III. To assess the association between TOPO2A status (TOPO2A gene copy number alterations
and TOPO2A protein expression), or chromosome 17 polysomy and clinical covariates (e.g.,
age, race/ethnicity, cell type, histologic grade, disease stage, regimen type).
IV. To assess the association between TOPO2A status or chromosome 17 polysomy with
measures of clinical outcome including response, progression-free survival, and overall
survival of patients treated with this regimen.
V. To evaluate the potential identification of cut points for TOPO2A protein expression
with potential prognostic value in patients treated with this regimen.
OUTLINE:
Archived tumor tissue samples are analyzed for topoisomerase 2-alpha gene alteration and
expression and chromosome 17 polysomy by fluorescent in situ hybridization (FISH) and
immunohistochemistry (IHC). Clinical information associated with each endometrial
carcinoma sample (e.g., age, race/ethnicity, cell type, histologic grade, disease stage,
and regimen type) is also collected.